{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:46:45Z","timestamp":1775843205230,"version":"3.50.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Sex differences exist in psoriasis manifestation and expectations from treatment with systemic agents, including, conventional systemic agents (CSA) and tumor necrosis factor inhibitors or ustekinumab (TNFi\/UST). However, sex differences in patterns of systemic agent use, such as CSA discontinuation and switch from CSA to TNFi\/UST have not been examined.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> To assess sex differences in patterns of CSA use and identify factors associated with switch to (or add) a TNFi\/UST and those associated with CSA discontinuation.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a retrospective cohort study using the Quebec health administrative databases. We included patients with psoriasis initiating a CSA in 2002\u20132015. We excluded patients with a psoriasis diagnosis in the 3\u00a0years prior to the first diagnosis date between 2002 and 2015, and those with a systemic agent dispensation in the year prior to that date. We used Cox regression models with the Least Absolute Shrinkage and Selection Operator method to identify factors associated with Switch\/add TNFi\/UST, and those associated with CSA discontinuation. Separate analyses were performed for male and female patients.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We included 1,644 patients (55.7% females, mean age 60.3\u00a0years), among whom 60.4% discontinued their CSA and 7.4%, switched\/added TNFi\/UST (3.4% switched and 4.0% added) within a median of 0.78\u00a0years of follow-up. Among male and female patients, rates of Switch\/add TNFi\/UST per 1,000 person-year were 49.1 and 41.0 and rates of CSA discontinuation were 381.2 and 352.8. Clinical obesity in male patients (HR 3.53, 95% CI 1.20\u201310.35), and adjustment\/somatoform\/dissociative disorders (HR 3.17, 95% CI 1.28\u20137.85) and use of nonsteroidal anti-inflammatory drugs (HR 2.70, 95% CI 1.56\u20134.70) in female patients were associated with Switch\/add TNFi\/UST. Male patients followed by a rheumatologist (HR 0.66, 95% CI 0.46\u20130.94) and those with a prior hospitalization (HR 0.70, 95% CI 0.57\u20130.87) were at lower risk of CSA discontinuation, while those initiated on acitretin (vs methotrexate) were at higher risk to discontinue their CSA (HR 1.61, 95% CI 1.30\u20132.01). Female patients with rheumatoid arthritis comorbidity (HR 0.69, 95% CI 0.51\u20130.93), those with a dispensed lipid-lowering agent (HR 0.72, 95% CI 0.59\u20130.88) and hypoglycemic agent (HR 0.75, 95% CI 0.57\u20130.98) and those initiated on methotrexate (vs all other CSAs) were less likely to discontinue their CSA. Male and female patients entering the cohort between 2011 and 2015 were at reduced risk of CSA discontinuation compared to those entering the cohort before 2011.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Most male and female patients discontinued their CSA within 1\u00a0year of follow-up. Our study highlighted sex differences in patients\u2019 characteristics associated with switch\/add a TNFi\/UST and CSA discontinuation; treatment switch and discontinuation may be indications of treatment failure in most patients.<\/jats:p>","DOI":"10.3389\/fphar.2022.810309","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T16:51:09Z","timestamp":1644943869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Sex Differences in the Patterns of Systemic Agent use Among Patients With Psoriasis: A Retrospective Cohort Study in Quebec, Canada"],"prefix":"10.3389","volume":"13","author":[{"given":"Raymond","family":"Milan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"LeLorier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Jos\u00e9e","family":"Brouillette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan V.","family":"Litvinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Rahme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"J254","DOI":"10.1016\/j.jaut.2011.12.001","article-title":"Sex Differences and Genomics in Autoimmune Diseases","volume":"38","author":"Amur","year":"2012","journal-title":"J. Autoimmun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis Prevalence in Adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14656566.2020.1849141","article-title":"An Update on the Impact of Depression on the Treatment of Psoriasis","author":"Bell","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/bjd.18734","article-title":"Persistence of Treatment with Conventional Systemic Agents for Patients with Psoriasis: a Real\u2010world Analysis of 73 168 New Users from the French National Health Insurance Database","volume":"182","author":"Bergqvist","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"B5","unstructured":"Adalimumab, Alefacept, Efalizumab, Etanercept, and Infliximab for Severe Psoriasis Vulgaris in Adults: Budget Impact Analysis and Review of Comparative Clinical- and Cost-Effectiveness2007"},{"key":"B6","volume-title":"Canadian Guidelines for the Management of Plaque Psoriasis","author":"Canadian Dermatology Association","year":"2009"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/pds.2034","article-title":"Sex--differences on Self-Medication in Spain","volume":"19","author":"Carrasco-Garrido","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjd.13288","article-title":"Elevated Odds of Metabolic Syndrome in Psoriasis: a Population-Based Study of Age and Sex Differences","volume":"172","author":"Danielsen","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of Classic and Biological Systemic Drugs in Psoriasis: Results of the BIOBADADERM Registry and Critical Analysis","volume":"30","author":"D\u00e1vila-Seijo","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.clinthera.2009.08.020","article-title":"Pattern and Predictors of the Initiation of Biologic Agents for the Treatment of Rheumatoid Arthritis in the United States: an Analysis Using a Large Observational Data Bank","volume":"31","author":"DeWitt","year":"2009","journal-title":"Clin. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000509732","article-title":"Sex and Age Influence the Associated Risk of Depression in Patients with Psoriasis: A Retrospective Population Study Based on Diagnosis and Drug-Use","author":"Duvetorp","year":"2020","journal-title":"Dermatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/JID.2015.350","article-title":"Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study","volume":"136","author":"Egeberg","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Awareness and Attention to Comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B14","unstructured":"Product Monograph, Immunex Corporation2000"},{"key":"B15","first-page":"36","article-title":"Psoriasis and Associated Psychiatric Disorders: A Systematic Review on Etiopathogenesis and Clinical Correlation","volume":"9","author":"Ferreira","year":"2016","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.14331","article-title":"Evaluating equality in Psoriasis Healthcare: a Cohort Study of the Impact of Age on Prescription of Biologics","volume":"174","author":"Geale","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"B17","first-page":"203","article-title":"Sex Differences in the Treatment of Psoriatic Arthritis: A Systematic Literature Review","volume":"18","author":"Generali","year":"2016","journal-title":"Isr. Med. Assoc. J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1203475416648323","article-title":"A Review of Psoriasis, Therapies, and Suicide","volume":"20","author":"Gooderham","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.exger.2016.12.021","article-title":"Sex Differences in Frailty: A Systematic Review and Meta-Analysis","volume":"89","author":"Gordon","year":"2017","journal-title":"Exp. Gerontol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical Response to Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: Double-Blind, Randomized Controlled Trial and Open-Label Extension Study","volume":"55","author":"Gordon","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40257-017-0274-0","article-title":"Severity of Psoriasis Differs between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients","volume":"18","author":"H\u00e4gg","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"B22","volume-title":"Regression Modeling Strategies - with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2011"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/03007995.2019.1618805","article-title":"Psoriasis Treatment Patterns: a Retrospective Claims Study","volume":"35","author":"Higa","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1002\/9780470258019","volume-title":"Applied Survical Analysis: Regression Modeling of Time-To-Event Data","author":"Hosmer","year":"2008"},{"key":"B25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1067\/mjd.2000.101596","article-title":"Sex-specific Differences in the Treatment of Severe Psoriasis","volume":"42","author":"Hotard","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"B26","unstructured":"Product Monograph, Abbvie Corporation2004"},{"key":"B27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1203475418814234","article-title":"Comparison of Management Guidelines for Moderate-To-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents","volume":"23","author":"Ighani","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2340\/00015555-0838","article-title":"A Multivariate Analysis of Clinical Severity, Psychological Distress and Psychopathological Traits in Psoriatic Patients","volume":"90","author":"Kotrulja","year":"2010","journal-title":"Acta Derm Venereol."},{"key":"B29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.54386\/jam.v21i2.231","article-title":"Comparison of Lasso and Stepwise Regression Technique for Wheat Yield Prediction","volume":"21","author":"Kumar","year":"2019","journal-title":"J. Agrometeorology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archdermatol.2010.370","article-title":"Prevalence of the Metabolic Syndrome in Psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006","volume":"147","author":"Love","year":"2011","journal-title":"Arch. Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the Efficacy and Tolerability of Biologic Therapies in Psoriasis: an Updated Network Meta\u2010analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2310\/7750.2009.08083","article-title":"The burden of Psoriasis and Barriers to Satisfactory Care: Results from a Canadian Patient Survey","volume":"13","author":"Mahler","year":"2009","journal-title":"J. Cutan. Med. Surg."},{"key":"B33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjd.17625","article-title":"Persistence and Effectiveness of Nonbiologic Systemic Therapies for Moderate-To-Severe Psoriasis in Adults: a Systematic Review","volume":"181","author":"Mason","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jdv.15324","article-title":"Gender and Age Significantly Determine Patient Needs and Treatment Goals in Psoriasis - a Lesson for Practice","volume":"33","author":"Maul","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 1. Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis with Biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors Predicting Persistence of Biologic Drugs in Psoriasis: a Systematic Review and Meta-Analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000156599","article-title":"Impact of Body Mass index and Obesity on Clinical Response to Systemic Treatment for Psoriasis. Evidence from the Psocare Project","volume":"217","author":"Naldi","year":"2008","journal-title":"Dermatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.12779","article-title":"Melanoma Associated with Tumour Necrosis Factor-\u03b1 Inhibitors: a Research on Adverse Drug Events and Reports (RADAR) Project","volume":"170","author":"Nardone","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"B39","unstructured":"Systemic Biological Therapy for Psoriasis2020"},{"key":"B40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/09546634.2017.1398393","article-title":"Drug Survival of Biologic Treatments in Psoriasis: a Systematic Review","volume":"29","author":"No","year":"2018","journal-title":"J. Dermatolog Treat."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jaad.2020.03.080","article-title":"Opioid Prescribing in Adults with and without Psoriasis","volume":"83","author":"Noe","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to Medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2310\/7750.2010.09066","article-title":"Epidemiology of Moderate-To-Severe Plaque Psoriasis in a Canadian Surveyed Population","volume":"14","author":"Papp","year":"2010","journal-title":"J. Cutan. Med. Surg."},{"key":"B44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis Prevalence Among Adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"B45","unstructured":"Rapport Annuel de Gestion 2014-2015 de La R\u00e9gie de l'assurance Maladie Du Qu\u00e9bec2015"},{"key":"B46","unstructured":"Liste des m\u00e9dicaments couverts2020"},{"key":"B47","unstructured":"Product Monograph, Janssen Inc2017"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent","volume":"39","author":"Simon","year":"2011","journal-title":"J. Stat. Softw."},{"key":"B49","unstructured":"Product Monograph, Janssen Inc2018"},{"key":"B50","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/jdv.16029","article-title":"Psoriasis, Cardiovascular Risk Factors and Metabolic Disorders: Sex-specific Findings of a Population-Based Study","volume":"34","author":"Sondermann","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B51","unstructured":"Product Monograph, Janssen Inc2017"},{"key":"B52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive Symptoms, Depression, and the Effect of Biologic Therapy Among Patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"78","author":"Strober","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjd.13560","article-title":"The 'switcher' Patient Profile in Psoriasis Treatment: from Traditional to Biological and from Biological to Traditional Systemic Drugs","volume":"173","author":"Tabolli","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.12039","article-title":"Adherence to Medication in Patients with Psoriasis: a Systematic Literature Review","volume":"168","author":"Thorneloe","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression Shrinkage and Selection via the Lasso","author":"Tibshirani","year":"1996","journal-title":"J. Roy Stat. Soc. Ser. B (Methodol)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and Clinical Outcomes, Fatigue, and Depression in Psoriasis: Double-Blind Placebo-Controlled Randomised Phase III Trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/00015550510036667","article-title":"Psoriasis Care Consumption and Expectations from a Gender Perspective in a Psoriasis Population in Northern Sweden","volume":"85","author":"Uttjek","year":"2005","journal-title":"Acta Derm Venereol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1468-3083.2011.04026.x","article-title":"Do men Have More Severe Psoriasis Than Women?","volume":"26","author":"White","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B59","unstructured":"Global report on psoriasis. World Health Organization\n            MichalekI. M.\n            LoringB.\n            JohnS. M.\n          2016"},{"key":"B60","unstructured":"Psoriasis: Report by the Secretariat2013"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e3816","DOI":"10.1097\/MD.0000000000003816","article-title":"Depression and Insomnia in Patients with Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/09546634.2017.1395800","article-title":"Epidemiology of Mental Health Comorbidity in Psoriasis","volume":"29","author":"Wu","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e4326","DOI":"10.7717\/peerj.4326","article-title":"Gender-associated Factors for Frailty and Their Impact on Hospitalization and Mortality Among Community-Dwelling Older Adults: a Cross-Sectional Population-Based Study","volume":"6","author":"Zhang","year":"2018","journal-title":"PeerJ"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.810309\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T16:51:20Z","timestamp":1644943880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.810309\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":63,"alternative-id":["10.3389\/fphar.2022.810309"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.810309","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"article-number":"810309"}}